Home
    Disclaimer
    4-Fluorophenibut molecular structure

    4-Fluorophenibut Stats & Data

    Baflofen Fluorobut Cgp-11130 F-phenibut Fluorophenibut
    Psychoactive Class Depressant
    Half-Life Unknown in humans; anecdotal reports suggest a shorter functional duration than phenibut (often 6–12 h of primary effects), with variability across users and batches.

    Pharmacology

    DrugBank

    Mechanism of Action

    F-phenibut acts as a potent agonist of the GABA-B receptor and in this regard is more similar to baclofen than phenibut.

    History & Culture

    F-Phenibut, designated by the developmental code name CGP-11130, is a GABA analogue that was investigated as a potential pharmaceutical agent but was never marketed. The compound belongs to a family of phenyl-substituted GABA derivatives that includes baclofen, tolibut, and phenibut, all of which share structural similarities as beta-phenyl-GABA analogues. Despite its origins in pharmaceutical research, F-Phenibut has more recently emerged as a novel psychoactive substance available through online research chemical vendors. The compound remains poorly characterized in the scientific literature, with limited formal research conducted on its pharmacological and toxicological properties.

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown in humans; anecdotal reports suggest a shorter functional duration than phenibut (often 6–12 h of primary effects), with variability across users and batches.
    Addiction Potential
    Moderate to high, similar to or greater than phenibut in practice. Dependence and withdrawal have been repeatedly reported after frequent or high-dose use.

    Tolerance Decay

    Full tolerance 3d Half tolerance 7d Baseline ~14d

    Community experience suggests tolerance accrues rapidly with consecutive-day use and decays over 1–3+ weeks; figures are indicative only and not clinically validated.

    Cross-Tolerances

    Phenibut
    70% ●○○
    Baclofen
    50% ●○○

    Experience Report Analysis

    Erowid
    7 Reports
    2016–2023 Date Range
    7 With Age Data
    8 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 7 experience reports (7 Erowid)

    7 Reports
    8 Effects Detected
    8 Positive
    0 Adverse
    0 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 8

    Euphoria 57.1% 70%
    Focus Enhancement 57.1% 70%
    Anxiety Suppression 57.1% 70%
    Color Enhancement 42.9% 70%
    Music Enhancement 42.9% 70%
    Stimulation 42.9% 70%
    Sedation 42.9% 70%
    Empathy 42.9% 70%

    Adverse Effects 0

    Real-World Dose Distribution

    62K Doses

    From 138 individual dose entries

    Oral (n=27)

    Median: 500.0mg 25th: 350.0mg 75th: 1500.0mg 90th: 1750.0mg
    mg/kg median: 3.454 mg/kg 75th: 4.869

    Rectal (n=110)

    Median: 1300.0mg 25th: 750.0mg 75th: 1600.0mg 90th: 1850.0mg

    Form / Preparation

    Most common forms and preparations reported

    Legal Status

    Country Status Notes
    Germany Not controlled Not scheduled under the Betäubungsmittelgesetz (BtMG). However, sale for human consumption would be regulated under §2 of the Arzneimittelgesetz (Medicines Act). Generally legal when sold as a research chemical or not marketed for consumption.
    Switzerland Not controlled Not listed under Buchstabe A, B, C, or D of the controlled substances regulations. Currently considered legal, though this status may be subject to change.
    United Kingdom Potentially illegal (PSA 2016) May be prohibited under the Psychoactive Substances Act 2016, which broadly restricts the production, supply, and importation of psychoactive substances. The Act provides exemptions for alcohol, nicotine, caffeine, and licensed medicinal products, but F-Phenibut does not fall under these exemptions.

    Harm Reduction

    drugs.wiki

    Potency vs phenibut is highly variable across individuals and lots; community moderators and experienced users typically estimate 4–8× stronger by weight, with reports spanning roughly 2–10×. Given this spread, first-time doses should be conservative (≤100 mg oral) with no redose for at least 3 hours to avoid stacking toward an unexpectedly heavy peak. Scoop sizes provided by vendors are unreliable; a milligram-accurate scale is strongly advised as community testing found vendor micro-scoops could vary several-fold depending on powder density and packing. The HCl salt is acidic and commonly causes gastric irritation/heartburn; taking in capsules or with non-acidic liquid may reduce discomfort, while the FAA form is sometimes used sublingually but tastes harsh and still requires precise weighing. Insufflation is discouraged due to acidity, high dose requirements, and lack of benefit; smoking or injection are strongly contraindicated. F-Phenibut appears more sedating and shorter-acting than phenibut for many users; profound next-day somnolence has been reported after higher doses, and users should avoid driving or hazardous tasks for the rest of the day and possibly the following morning. Mixing with alcohol, GHB/GBL, benzodiazepines, opioids, or other sedatives meaningfully increases risk of blackouts, aspiration, and respiratory depression; avoid these combinations entirely. Tolerance can develop within days of repeated use; many HR communities recommend limiting use to once or twice per week with multi-day gaps to reduce dependence risk. Withdrawal after sustained or high-dose use can onset more rapidly than with phenibut (sometimes within 10–24 hours), and may include anxiety, insomnia, tachycardia, tremor, and rebound agitation; abrupt cessation from daily use is discouraged—seek medical guidance for a gradual taper. Adulteration and mislabeling occur in this market; drug checking services have found samples sold as phenibut that contained other substances (e.g., CBD), so treat unknown material cautiously and test when possible. A subset of users report paradoxical or dysphoric reactions, dizziness, and chest discomfort at higher doses; any chest pain, severe confusion, or breathing difficulty warrants urgent medical evaluation.

    ← Back to 4-Fluorophenibut